Lexicon Pharmaceuticals Inc (LXRX)

Apr 17, 2026

Significant First Quarter Growth for LXRX Driven by New Client R - GuruFocus

Apr 17, 2026

Apr 17, 2026

Lexicon (LXRX) Advances Pilavapadin After Positive Phase 2b Stud - GuruFocus

Apr 17, 2026

Apr 17, 2026

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting - The Manila Times

Apr 17, 2026

Apr 17, 2026

New Lexicon data back a 10 mg diabetic nerve pain dose for Phase 3 - Stock Titan

Apr 17, 2026

Apr 16, 2026

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 1-Year HighHere's Why - MarketBeat

Apr 16, 2026

Apr 12, 2026

Lexicon Pharmaceuticals Q2 2025 Earnings Preview - MSN

Apr 12, 2026

Apr 11, 2026

Growth Report: What is the target price for Lexicon Pharmaceuticals Inc stock2026 Update & Weekly High Return Opportunities - baoquankhu1.vn

Apr 11, 2026

Apr 11, 2026

IPO Launch: Is Lexicon Pharmaceuticals Inc stock trending bullish2026 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

LXRX SEC FilingsLexicon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 10, 2026

Apr 10, 2026

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week HighShould You Buy? - MarketBeat

Apr 10, 2026

Apr 09, 2026

LXRX stock up as NVO initiates phase I study of partnered obesity drug - MSN

Apr 09, 2026

Apr 08, 2026

Buyback Watch: Can Lexicon Pharmaceuticals Inc reach all time highs this year2026 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Lexicon Pharmaceuticals, Inc. (LXRX) stock price, news, quote and history - Yahoo Finance UK

Apr 07, 2026

Apr 07, 2026

Lexicon Pharmaceuticals (LXRX) price target increased by 15.07% to 3.43 - MSN

Apr 07, 2026

Apr 06, 2026

How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation Assumptions - Yahoo Finance

Apr 06, 2026

Apr 04, 2026

LXRX Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 04, 2026

Lexicon Pharmaceuticals, Inc. (LX31.MU) stock price, news, quote and history - Yahoo Finance UK

Apr 04, 2026

Apr 02, 2026

Lexicon Pharmaceuticals joins Texas Life Sciences Summit to engage industry leaders and drive sector momentum - Traders Union

Apr 02, 2026

Apr 02, 2026

LXRX Stock Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill

Apr 02, 2026

Apr 01, 2026

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% HigherTime to Buy? - MarketBeat

Apr 01, 2026

Mar 31, 2026

Certain Stock Options of Lexicon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com

Mar 31, 2026

Mar 31, 2026

Certain Restricted Stock Units of Lexicon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com

Mar 31, 2026

Mar 31, 2026

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat

Mar 31, 2026

Mar 30, 2026

Lexicon Pharmaceuticals unveils ACC26 trial analysis on BMI and cardiovascular outcomes - Traders Union

Mar 30, 2026

Mar 29, 2026

Published on: 2026-03-29 16:03:42 - baoquankhu1.vn

Mar 29, 2026

Mar 28, 2026

Lexicon Pharmaceuticals unveils new SOTA‑P‑CARDIA Chapter 2 data in HFpEF at ACC26 - Traders Union

Mar 28, 2026

Mar 27, 2026

Lexicon Pharmaceuticals Stock: Pipeline Progress and Financial Strategy in Biopharma Sector - AD HOC NEWS

Mar 27, 2026

Mar 26, 2026

ACC meeting features Lexicon Pharmaceuticals clinical research presentations - Traders Union

Mar 26, 2026

Mar 24, 2026

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug - Yahoo Finance

Mar 24, 2026

Mar 24, 2026

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo - Bitget

Mar 24, 2026

Mar 24, 2026

Lexicon brings ACC data showing heart benefits across BMI groups - Stock Titan

Mar 24, 2026

Mar 23, 2026

Lexicon Pharmaceuticals (LXRX) Receives Reiterated Buy Rating at $6.00 | LXRX Stock News - GuruFocus

Mar 23, 2026

Mar 23, 2026

Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright - marketbeat.com

Mar 23, 2026

Mar 23, 2026

Novo Nordisk Begins Study of Lexicon Oral Obesity Drug - wsj.com

Mar 23, 2026

Mar 23, 2026

Lexicon Pharmaceuticals And Novo Nordisk Announce Initiation Of Phase 1 Study With Oral Obesity Drug Candidate LX9851 - TradingView

Mar 23, 2026

Mar 23, 2026

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 - Yahoo Finance

Mar 23, 2026

Mar 22, 2026

HC Wainwright remains a buy on Lexicon Pharmaceuticals (LXRX) - MSN

Mar 22, 2026

Mar 22, 2026

Published on: 2026-03-22 17:56:17 - baoquankhu1.vn

Mar 22, 2026

Mar 21, 2026

LXRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 21, 2026

Mar 20, 2026

H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) - Insider Monkey

Mar 20, 2026

Mar 19, 2026

Lexicon Pharmaceuticals advances chronic pain treatment options with focus on non opioid innovation - Traders Union

Mar 19, 2026

Mar 18, 2026

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - MSN

Mar 18, 2026